Loading company…
Basel-based biopharmaceutical company developing therapies for rare diseases, acquired by Pfizer in 2019.
Therachon AG develops biopharmaceuticals for rare diseases, using biologic treatments and targeted drug combinations. It generates revenue through partnerships with healthcare systems and direct therapy sales, mainly to hospitals, clinics and retail pharmacies. Founded in 2014 in Basel, Switzerland, the company is at Series A stage and was acquired by Pfizer Inc. in May 2019 for USD 340.00 mn, with up to USD 470.00 mn more tied to development and commercialization milestones.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in